We are pleased to announce that we have received approval from the MHRA (UK) and T-FDA (Thailand) to initiate a new phase I/II clinical trial for KRC-01 in cervical cancer.
This is a global study to evaluate the safety and preliminary efficacy of KRC-01 in combination with chemoradiation therapy in locally advanced cervical cancer patients who have not received prior treatment (NCT05570422).
This study will be expanded to the United States, India, and South Korea, in addition to the United Kingdom and Thailand. For more information, please visit:
https://classic.clinicaltrials.gov/ct2/show/NCT05570422
About KRC-01:
Radiation therapy is an established cancer treatment along with surgery and drug therapy, and about 60% of cancer patients worldwide receive radiation therapy each year.
However, as tumors grow larger, hypoxia occurs inside the tumor, reducing the effectiveness of radiation therapy. This phenomenon has long been recognized as a problem of radiation therapy resistance, but no solution has yet been found.
Direct injection of KRC-01 into the tumor prior to radiation therapy is expected to eliminate this hypoxia problem by supplying oxygen to the tumor and eliminating Hypoxia, thereby producing a radiosensitizing effect.